Clinical Trials Directory

Trials / Completed

CompletedNCT01578421

Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
31 (actual)
Sponsor
Kantonsspital Aarau · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to compare clearance and removal rates of phosphate, ß2-microglobulin (ß2-m) and leptin and albumin loss with different dialyser membranes during post-dilution online hemodiafiltration.

Conditions

Interventions

TypeNameDescription
DEVICE4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements

Timeline

Start date
2012-02-01
Primary completion
2012-09-01
Completion
2012-12-01
First posted
2012-04-17
Last updated
2013-08-07

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT01578421. Inclusion in this directory is not an endorsement.

Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and (NCT01578421) · Clinical Trials Directory